Boston Medical Sciences, Developer of Cathartic-Free Virtual Endoscopy™, Wins Grand Prix at "Forbes JAPAN RISING STAR AWARD 2026"
Boston Medical Sciences received the Grand Prix at the "RISING STAR AWARD 2026" hosted by Forbes JAPAN. The company aims to contribute to the early detection and prevention of colorectal cancer through the development of Cathartic-Free Virtual Endoscopy™.
📋 Article Processing Timeline
- 📰 Published: May 7, 2026 at 18:00
- 🔍 Collected: May 7, 2026 at 09:31
- 🤖 AI Analyzed: May 7, 2026 at 09:37 (5 min after Collected)
We are pleased to announce that Masaki Okamoto, Representative Director and CEO of Boston Medical Sciences Inc. (Headquarters: Chuo-ku, Tokyo; hereinafter "the Company"), received the Grand Prix at the "RISING STAR AWARD 2026" event, hosted by Forbes JAPAN. The event, targeting startup entrepreneurs founded within three years, was held on April 16 at Ebisu Garden Place in Tokyo.
Entrepreneurs expected to grow into next-generation unicorn companies presented at this event. From over 130 applicants, seven companies that passed the preliminary screening by the Forbes JAPAN editorial department proceeded to pitch. The judging panel consisted of four investors selected for the 2026 edition of "Japan's Most Influential Venture Investors Ranking," annually published by the magazine.
(Judges)
Tomoyuki Nii (Executive Officer, Head of Overseas Investment, SBI Investment)
Akira Nagashima (Chief Capitalist, Jafco Group)
Kazuhiko Ishikura (Representative Director and President, Akatsuki Ventures / Representative Partner, Dawn Capital)
Naohiro Mizumoto (Representative Director Partner, Ant Innovations)
On the day of the event, startups from various fields, including our company's AI medical initiatives, autonomous driving, materials development, sharing services, and marine observation, made presentations.
We interpret this award as a widespread recognition of the significance of the challenges we have undertaken. Moving forward, under the philosophy of "eradicating colorectal cancer deaths from the world through the power of early detection and prevention," we will continue to work on transforming medical care through the research, development, and social implementation of Cathartic-Free Virtual Endoscopy™, striving to deliver value to even more people.
Company Overview
Headquarters: MFPR Nihonbashi Honcho Bldg. 3F B-PORT, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo
R&D Base: 2F, 14-10 Nihonbashi Kodenmacho, Chuo-ku, Tokyo (BMS Research)
Established: April 2023
Founder & Representative: Masaki Okamoto
Main Business: Research and development, and clinical implementation of non-invasive colorectal cancer screening AI systems
URL: https://b-ms.tech
Entrepreneurs expected to grow into next-generation unicorn companies presented at this event. From over 130 applicants, seven companies that passed the preliminary screening by the Forbes JAPAN editorial department proceeded to pitch. The judging panel consisted of four investors selected for the 2026 edition of "Japan's Most Influential Venture Investors Ranking," annually published by the magazine.
(Judges)
Tomoyuki Nii (Executive Officer, Head of Overseas Investment, SBI Investment)
Akira Nagashima (Chief Capitalist, Jafco Group)
Kazuhiko Ishikura (Representative Director and President, Akatsuki Ventures / Representative Partner, Dawn Capital)
Naohiro Mizumoto (Representative Director Partner, Ant Innovations)
On the day of the event, startups from various fields, including our company's AI medical initiatives, autonomous driving, materials development, sharing services, and marine observation, made presentations.
We interpret this award as a widespread recognition of the significance of the challenges we have undertaken. Moving forward, under the philosophy of "eradicating colorectal cancer deaths from the world through the power of early detection and prevention," we will continue to work on transforming medical care through the research, development, and social implementation of Cathartic-Free Virtual Endoscopy™, striving to deliver value to even more people.
Company Overview
Headquarters: MFPR Nihonbashi Honcho Bldg. 3F B-PORT, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo
R&D Base: 2F, 14-10 Nihonbashi Kodenmacho, Chuo-ku, Tokyo (BMS Research)
Established: April 2023
Founder & Representative: Masaki Okamoto
Main Business: Research and development, and clinical implementation of non-invasive colorectal cancer screening AI systems
URL: https://b-ms.tech